We found that, in NASH, hepatic Laptm5 deficiency caused the upregulation of a wide array of pathways and genes that promote lipid metabolism, inflammation, and fibrosis (Fig. 5k–n). This evidence concerns the gene LAPTM5 and metabolic dysfunction-associated steatohepatitis.